Epidermal Growth Factor Receptor and Bladder Cancer

Urologia Internationalis 48, 365-371 DOI: 10.1159/000282357

Citation Report

#	Article	IF	CITATIONS
1	Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies. The Clinical Investigator, 1993, 71, 898-902.	0.6	7
2	Molecular prognostic factors in bladder cancer. World Journal of Urology, 1994, 12, 84-8.	2.2	24
3	câ€ <i>jun</i> oncogene expression in transitional cell carcinoma of the urinary bladder. British Journal of Urology, 1994, 74, 757-761.	0.1	36
4	Growth factors in bladder cancer. World Journal of Urology, 1995, 13, 349-55.	2.2	14
5	The Prognostic Role of Alterations of the p53 Tumor Suppressor Gene in Superficial and Advanced Stage Bladder Cancer. Oncology Research and Treatment, 1995, 18, 202-210.	1.2	1
6	Cytokine modulation of epidermal growth factor receptor expression on bladder cancer cells is not a major contributor to the antitumour activity of cytokines. European Journal of Cancer, 1995, 31, 2059-2066.	2.8	11
7	Species comparison of the content and composition of urinary proteins. Food and Chemical Toxicology, 1995, 33, 731-746.	3.6	31
8	Chronic treatment with epidermal growth factor stimulates growth of the urinary tract in the rat. Urological Research, 1996, 24, 15-21.	1.5	16
9	Enhanced gene expression of transforming growth factor-? and c-met in rat urinary bladder cancer. Urological Research, 1996, 24, 55-60.	1.5	17
10	Molecular biology of dissemination in bladder cancer ? laboratory findings and clinical significance. World Journal of Urology, 1996, 14, 190-6.	2.2	3
11	Contractile and cytoskeletal proteins in urinary bladder smooth muscle from rats treated with epidermal growth factor. Urological Research, 1996, 24, 229-234.	1.5	6
12	Oncogene Expression and Amplification in Barrett Adenocarcinoma. International Journal of Surgical Pathology, 1997, 4, 203-211.	0.8	2
13	Epidemiologie und Biologie des Harnblasenkarzinoms. Onkologe, 1997, 3, 218-226.	0.7	0
14	Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urological Research, 1997, 25, 9-17.	1.5	78
15	Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines. , 1997, 70, 383-389.		10
16	Expression of epidermal growth factor receptor in urinary bladder cancer metastases. , 1998, 76, 189-193.		47
17	Prognostic significance of glutathione S-transferase π and c-Jun in epithelial ovarian cancers. International Journal of Clinical Oncology, 1998, 3, 281-286.	2.2	2
18	The effects of exogenous epidermal growth factor on the developing urinary tract in rats: a stereological description. Urological Research, 1998, 26, 105-110.	1.5	6

#	Article	IF	CITATIONS
19	Impact of the Expression of Epidermal Growth Factor, Transforming Growth Factor Alpha, and Epidermal Growth Factor Receptor on the Prognosis of Superficial Bladder Cancer. Urology, 1998, 51, 645-649.	1.0	44
20	Significance of Multiâ€Ðrugâ€Resistant Proteins in Predicting Chemotherapy Response and Prognosis in Epithelial Ovarian Cancer*. Journal of Obstetrics and Gynaecology Research, 1999, 25, 387-394.	1.3	39
21	Pharmacological effects of epidermal growth factor (EGF) with focus on the urinary and gastrointestinal tracts. Apmis, 1999, 107, 5-42.	2.0	12
22	Intravesical Administration of EGF– Dextran Conjugates in Patients with Superficial Bladder Cancer. European Urology, 2000, 38, 584-589.	1.9	10
23	Epidemiology and biology of human urinary bladder cancer. Journal of Cancer Research and Clinical Oncology, 2000, 126, 575-583.	2.5	21
24	Binding of 125I after administration of 125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer spheroids International Journal of Oncology, 2000, 17, 559-64.	3.3	1
25	Profile of epidermal growth factor receptor (EGFr) expression in human malignancies: effects of exposure to EGF and its biological influence on established human tumour cell lines International Journal of Molecular Medicine, 2000, 6, 495-500.	4.0	17
26	Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nuclear Medicine and Biology, 2000, 27, 827-835.	0.6	36
27	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. Journal of Urology, 2001, 165, 1152-1157.	0.4	15
28	The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU International, 2001, 83, 1039-1044.	2.5	26
29	The Expression of Oncoproteins in Transitional Cell Carcinoma: Its Correlation with Pathological Behavior, Cell Cycle and Drug Resistance. Urologia Internationalis, 2002, 69, 46-50.	1.3	10
30	Internalisation and retention of EGF-dextran associated radioactivity in transfected Chinese hamster ovary cells expressing the human EGF-receptor. International Journal of Oncology, 2002, 20, 1057.	3.3	1
31	Clasificación y factores pronósticos de los tumores epiteliales de vejiga. EMC - UrologÃa, 2002, 34, 1-6.	0.0	0
32	Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?. Urological Research, 2002, 30, 273-281.	1.5	31
33	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study. Head and Neck, 2003, 25, 864-872.	2.0	165
34	Novel approaches with targeted therapies in bladder cancer. Critical Reviews in Oncology/Hematology, 2003, 46, 85-104.	4.4	113
35	Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran. Nuclear Medicine and Biology, 2003, 30, 303-315.	0.6	23
36	Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer. Clinical Cancer Research, 2004, 10, 4874-4884.	7.0	78

CITATION REPORT

#	Article	IF	CITATIONS
37	1311-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR. Nuclear Medicine and Biology, 2004, 31, 435-440.	0.6	6
38	The Significance of Serum Soluble Intercellular Adhesion Molecule 1 and Transforming Growth Factor I± in Patients With Nasopharyngeal Carcinoma. JAMA Otolaryngology, 2004, 130, 1205.	1.2	13
39	Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens. Cytopathology, 2005, 16, 303-308.	0.7	7
40	Chemoprevention of lung cancer: concepts and strategies. Expert Review of Anticancer Therapy, 2005, 5, 549-565.	2.4	4
41	Clinical Applications for Targeted Therapy in Bladder Cancer. Urologic Clinics of North America, 2005, 32, 239-246.	1.8	10
42	Overexpression of laminin-5 γ2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor, and human epidermal growth factor 2. Human Pathology, 2005, 36, 522-530.	2.0	40
43	The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 72-81.	2.4	86
44	Chemoprevention of bladder cancer. World Journal of Urology, 2006, 24, 445-472.	2.2	22
45	Developing innovative strategies for advanced transitional cell carcinoma of the bladder. Expert Review of Anticancer Therapy, 2006, 6, 83-92.	2.4	4
46	Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapy. Expert Opinion on Biological Therapy, 2007, 7, 555-568.	3.1	117
48	Small-molecule inhibitors of the human epidermal receptor family. Expert Opinion on Investigational Drugs, 2009, 18, 1829-1842.	4.1	25
49	Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Molecular Cancer, 2009, 8, 94.	19.2	48
50	A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecologic Oncology, 2010, 118, 308-312.	1.4	59
51	FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. PLoS ONE, 2010, 5, e13821.	2.5	258
52	Pathobiology and Chemoprevention of Bladder Cancer. Journal of Oncology, 2011, 2011, 1-23.	1.3	21
53	Exploring molecular genetics of bladder cancer: lessons learned from mouse models. DMM Disease Models and Mechanisms, 2012, 5, 323-32.	2.4	40
54	Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity. Journal of Experimental and Clinical Cancer Research, 2013, 32, 101.	8.6	16
55	The Diversity of 68Ga-Based Imaging Agents. Recent Results in Cancer Research, 2013, 194, 101-131.	1.8	11

	CITATION R	CITATION REPORT		
#	Article	IF	Citations	
56	The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer. , 0, , .		4	
57	Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. Molecular Pharmaceutics, 2016, 13, 534-544.	4.6	13	
58	Sleeping beauty: awakening urothelium from its slumber. American Journal of Physiology - Renal Physiology, 2017, 312, F732-F743.	2.7	44	
59	Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer. Frontiers in Pharmacology, 2017, 8, 977.	3.5	13	
60	ALDOLASE A regulates invasion of bladder cancer cells via Eâ€cadherinâ€EGFR signaling. Journal of Cellular Biochemistry, 2019, 120, 13694-13705.	2.6	21	
61	Diphtheria Toxin Fusion Proteins. Current Topics in Microbiology and Immunology, 1998, 234, 63-81.	1.1	36	
62	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. Journal of Urology, 2001, , 1152-1157.	0.4	2	
63	The Potential of EGFR-Targeted Agents in Cancer Prevention. , 2004, , 317-324.		1	
64	Molecular Biology and Bladder Cancer. , 1994, , 19-45.		1	
66	Radiolabeled Peptide Probes for Liver Cancer Imaging. Current Medicinal Chemistry, 2020, 27, 6968-6986.	2.4	8	
68	Chronic systemic treatment with epidermal growth factor in pigs causes pronounced urothelial growth with accumulation of glycoconjugates. American Journal of Pathology, 1995, 147, 1330-8.	3.8	10	
69	Targeted therapies in the management of metastatic bladder cancer. Biologics: Targets and Therapy, 2007, 1, 393-406.	3.2	8	
70	Analysis of and genes in patients with bladder cancer. Medical Journal of the Islamic Republic of Iran, 2020, 34, 108.	0.9	1	
72	TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB. Cancers, 2022, 14, 4809.	3.7	6	